The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Hypomethylating agents (HMA) + venetoclax (Ven) is the current standard of care for patients with newly diagnosed acute myeloid leukemia aged ≥75 years old or who are ineligible for intensive chemotherapy. This consensus is based on results obtained from a phase Ib trial (NCT02203773) and the phase III VIALE-A trial (NCT02993523).1 However, even though it is low intensity, the regimen places a significant burden on patients due to myelosuppression, bone marrow assessments, and an indefinite treatment period.1
Here, we summarize a real-world study published by Abaza et al.1 in American Journal of Hematology on efficacy, safety, and survival outcomes of HMA + Ven in elderly patients with newly diagnosed acute myeloid leukemia.
Figure 1. A ELN risk stratified CR/CRi rate, B 4-gene prognostic model stratified CR/CRi rate, C ELN risk stratified median OS, and D 4-gene prognostic model stratified median OS*
CR, complete response; CRi, CR with incomplete count recovery; ELN, European LeukemiaNet; OS, overall survival.
*Adapted from Abaza, et al.1
Key learnings |
|
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content